Skip to main content

Fiscal Wizard · Single-issue tearsheet

ARGX / Jun 21, 2026 Run #7397

ARGX

argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Composite verdict

A 78.6 / 100
Bullish setup · Trend Following 17 drivers · 3 gates blocking
  • Fibonacci Retracement
  • Trendline Break
  • Star
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 20th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile uptrend
Bull 100%Evidence: High · 18 signals0% Bear
Momentum Bullish 96Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -91%
Asset value $117.76Earnings power value $204.24Price $877.72

Priced above its no-growth earnings power value ($204.24/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

57.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 100
Margin of Safety 0
Return on Assets 86
Cash Conversion 0
Return on Capital Employed 85
Earnings Yield 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Fibonacci Retracement, Trendline Break, Star); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Fibonacci Retracement 91
Trendline Break 89
Vortex Signal 85

Risk Gates

3 blocking 4 caution

3 guards active, 22 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ARGX.